{
    "clinical_study": {
        "@rank": "146099", 
        "arm_group": [
            {
                "arm_group_label": "dexmedetomidine-remifentanil", 
                "arm_group_type": "Experimental", 
                "description": "intravenous infusion of 0.2-0.7 \u00b5g/kg/h of dexmedetomidine after a loading dose of 1 \u00b5g/kg over 10 min"
            }, 
            {
                "arm_group_label": "midazolam-remifentanil", 
                "arm_group_type": "Active Comparator", 
                "description": "remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Cardiac ablation is an invasive procedure requiring anesthetic support for immobility and\n      analgesia.  Benzodiazepines and opioids are the most commonly used agents, while they are\n      associated with respiratory depression and hypotension. The aim of this study was to compare\n      the effect of remifentanil and dexmedetomidine, which exerts sedative and analgesic effect\n      without serious respiratory depression, with conventional midazolam/remifentanil combination\n      on sedative and analgesic levels in patients undergoing endocardial ablation."
        }, 
        "brief_title": "Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Cardiac Arrhythmia", 
        "condition_browse": {
            "mesh_term": "Arrhythmias, Cardiac"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients scheduled for elective cardiac ablation for atrial fibrillation\n\n        Exclusion Criteria:\n\n          -  ASA physical status class \u2265 3,\n\n          -  respiratory disease,\n\n          -  end stage renal disease,\n\n          -  illiterate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652586", 
            "org_study_id": "1-2011-0008"
        }, 
        "intervention": [
            {
                "arm_group_label": "dexmedetomidine-remifentanil", 
                "intervention_name": "dexmedetomidine-remifentanil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "midazolam-remifentanil", 
                "intervention_name": "midazolam-remifentanil", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Midazolam", 
                "Dexmedetomidine", 
                "Remifentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "cardiac ablation", 
        "lastchanged_date": "July 27, 2012", 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Severance Hospital", 
            "last_name": "Young Lan Kwak, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Ramsay sedation score (1 = anxious and agitated, restless; 2 = cooperative, oriented, tranquil; 3 = responsive to verbal commands, drowsy; 4 = asleep, responsive to light stimulation; 5 = asleep, slow response to stimulation; 6 = no response to stimulation)\nthe bispectral index", 
            "measure": "change of sedation depth", 
            "safety_issue": "No", 
            "time_frame": "5 min after study drug adminstration, and every 10 min thereafter"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652586"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}